Chimeric antigen receptor (CAR) T-cell therapy is a novel and highly efficacious immunotherapeutic modality, that generated hitherto unseen remission rates in relapsed/refractory B-cell malignancies and multiple myeloma, and that could be an attractive option for TP53-mutant AML/MDS as well (Berdeja et al, 2021; Davila et al, 2014; Kochenderfer et al, 2015; Lee et al, 2015a; Maude et al, 2014; Munshi et al, 2021; Neelapu et al, 2017; Schuster et al, 2019; Turtle et al, 2016a). Here, TP53 is linked to myelodysplastic syndrome.